| Project/Area Number |
24791531
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
ANDO Takashi 山梨大学, 医学工学総合研究部, 助教 (10377492)
|
|---|
| Research Collaborator |
HARO Hirotaka 山梨大学, 医学工学総合研究部, 教授 (10313264)
SATO Nobutaka 山梨大学, 医学工学総合研究部, 助教 (00418716)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 骨・軟部腫瘍学 / ｍＴＯＲ / 骨肉腫 / ゲムシタビン / mTOR / Gemcitabine / osteosarcoma / LM8 / lung metastasis |
|---|
| Research Abstract |
mTOR inhibitor (Rapamycin) induced significant tumor growth inhibitory effect on mouse osteosarcoma cell line (LM8) by in vitro study as WB assay, WST assay, microscopic analysis and FACS analysis. Additive effect was observed by combining another anticancer agent (gemcitabine). mTOR inhibitor (rapamycin) induced the growth inhibition of primary tumor and suppression of lung metastasis in in vivo experiments using the osteosarcoma (LM8) tumor-bearing mouse model transplanted to C3H mice. Furthermore, same additive effect as in vitro study with the combination anti-cancer agent (gemcitabine) were observed in this mouse model study.
|
